Read on to learn why. Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks. Make smarter investments with weekly expert stock picks from the ...

Pfizer's strong R&D pipeline, 7.5%+ dividend yield, & undervalued PE ratio make PFE stock a compelling investment opportunity ...

In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 50 new drugs. The CDER director, Patrizia ...

Pfizer stock shows strong potential with updates on danuglipron, robust cost controls, and attractive valuations. Learn more ...

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

Moreover, some of Pfizer’s products may face patent expirations soon, which may impact the company. Hence, those willing to buy shares of Pfizer must wait patiently for further catalysts ...

Pfizer does face several risks that investors should weigh carefully. For instance, competition is increasing for two key products. Prevnar, Pfizer's blockbuster pneumococcal vaccine, faces ...

Forecasting ahead to 2025, Pfizer reaffirmed its full-year guidance, with revenue of $6164 billion, as well as adjusted EPS of $2.80$3.00. This reflects stability in the face of expected IRA ...